Last reviewed · How we verify
INKT
At a glance
| Generic name | INKT |
|---|---|
| Also known as | In vitro expanded autologous invariant natural killer T cells |
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases (EARLY_PHASE1)
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS (PHASE1)
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (PHASE2)
- Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)
- GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma (PHASE2)
- Molecular Basis of Food Allergy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INKT CI brief — competitive landscape report
- INKT updates RSS · CI watch RSS
- Beth Israel Deaconess Medical Center portfolio CI